# Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

> **NCT02292225** · PHASE1 · TERMINATED · sponsor: **SecuraBio** · enrollment: 3 (actual)

## Conditions studied

- Lymphocytic Leukemia, Chronic
- Lymphoma, Small Lymphocytic

## Interventions

- **DRUG:** IPI-145 (duvelisib)
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT02292225
- **Lead sponsor:** SecuraBio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** The scope of the program has been reduced to focus resources on studies which can potentially enable the registration of duvelisib.
- **Last updated:** 2023-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02292225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02292225, "Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02292225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*